Terminated × Leukemia × Antilymphocyte Serum × Clear all
NCT01116232 2019-03-26

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
4 enrolled 4 charts
NCT00290628 2017-11-29

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
43 enrolled
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT00719849 2017-06-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
13 enrolled 24 charts
NCT00608517 2014-05-20

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
6 enrolled 13 charts
NCT00005641 2012-12-11

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
NCT00005852 2012-12-11

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
NCT00827099 2012-03-23

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

Northside Hospital, Inc.

Phase 2 Terminated
5 enrolled 5 charts